Remdesivir Shows Promising Results In Leaked Report But Doubts Remain

No Comparator Arm One Issue?

Gilead’s front-running antiviral to fight the coronavirus has shown rapid improvement in severe patients’ symptoms in one US study but some are not convinced.

Coronavirus 2019-nCoV Blood Sample. Corona virus outbreaking. Epidemic virus Respiratory Syndrome. China
REMDESIVIR SHOWS PROMISING RESULTS BUT DOUBTS REMAIN • Source: Shutterstock

In leaked results from a University of Chicago study, Gilead Sciences Inc.’s antiviral remdesivir showed large improvements in some patients with the most severe form of COVID-19, the respiratory disease caused by SARS-CoV-2.

Out of an initial 125 patients who received the drug in the trial, one of two Phase III clinical programs...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip